Loading
MagnetisMM-3, trial NCT04649359 sponsored by Pfizer and reported in 2023, is the pivotal single-arm study behind elranatamab's approval in relapsed or refractory myeloma after at least three prior lines in BCMA-naive patients. In 123 patients the response rate was 61 percent with complete response or better in 35 percent, progression-free survival was durable, and switching to every-two-week dosing after six months maintained responses. OnCo links it to multiple myeloma, elranatamab and the MagnetisMM-3 paper. Whether reduced dosing frequency lowers infection risk without losing efficacy is the open question its design raised.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Elranatamab, Pfizer (incl. Seagen), T-cell engagers (bispecific), Multiple myeloma.
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Shares Elranatamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Elranatamab, Relapsed or refractory multiple myeloma, Pfizer (incl. Seagen), T-cell engagers (bispecific).
Shares Elranatamab, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Shares Elranatamab, Relapsed or refractory multiple myeloma, Pfizer (incl. Seagen), T-cell engagers (bispecific).
Shares Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.